Share Price and Basic Stock Data
Last Updated: December 24, 2025, 6:18 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vaishali Pharma Ltd operates in the pharmaceutical sector, with its stock currently priced at ₹9.29 and a market capitalization of ₹121 Cr. The company reported sales of ₹70 Cr for FY 2023, reflecting a decline from ₹76 Cr in FY 2022. However, a positive trend emerged in the trailing twelve months (TTM), where sales rose to ₹117 Cr. Quarterly sales data shows significant fluctuations; the highest reported was ₹32.40 Cr in Mar 2024, while the lowest was ₹10.18 Cr in Jun 2022. This inconsistency highlights volatility in revenue generation, which could be attributed to market dynamics or operational challenges. The company’s operating profit margin (OPM) for FY 2023 stood at 13%, a stark improvement from just 9% in FY 2022. Despite a challenging environment, Vaishali Pharma has shown resilience, with sales reaching ₹27.90 Cr in Dec 2023. The upcoming quarters will be critical as the company aims to stabilize revenue and improve operational efficiency.
Profitability and Efficiency Metrics
Vaishali Pharma’s profitability metrics reveal a mixed performance. The return on equity (ROE) stood at 1.52%, while return on capital employed (ROCE) was recorded at 4.93%. The company’s operating profit margin (OPM) for the trailing twelve months was 5.77%, indicating a significant decline from previous periods, particularly from 13% in FY 2023. This decline raises concerns about cost management and operational efficiency. The interest coverage ratio (ICR) was reported at 2.08x, suggesting that the company can cover its interest obligations comfortably, although it is at the lower end of the spectrum. Notably, the net profit for FY 2023 was stagnant at zero, which is concerning given the overall sales figures. The cash conversion cycle (CCC) of 77 days indicates a relatively efficient operational cycle, although improvements can be made to enhance liquidity. Overall, while profitability is constrained, the company’s ability to manage expenses will be crucial in the coming quarters.
Balance Sheet Strength and Financial Ratios
Vaishali Pharma’s balance sheet shows a total debt of ₹16 Cr against reserves of ₹41 Cr, indicating a manageable debt level. The company’s current ratio is reported at 2.61, which is well above the industry average, suggesting strong liquidity. The debt-to-equity ratio stands at 0.17, reflecting a conservative leverage position that minimizes financial risk. However, the company’s price-to-book value (P/BV) ratio is at 2.53x, which may indicate that the stock is overvalued compared to its book value of ₹4.98 per share. The interest coverage ratio of 2.08x indicates that the company can meet its interest obligations, albeit with limited margin for error. The asset turnover ratio of 1.04% suggests efficient use of assets in generating sales. Overall, while the balance sheet appears stable, the elevated P/BV ratio and stagnant net profit raise concerns about long-term growth potential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Vaishali Pharma reflects a diverse ownership structure. Promoters hold 26.32% of the shares, while the public holds a substantial 73.68%. Foreign institutional investors (FIIs) have not shown significant interest, with a 0% stake reported, which could imply a lack of confidence among international investors. The number of shareholders has increased to 27,752, indicating growing interest at the retail level. However, the absence of institutional backing may limit the stock’s potential for significant price appreciation. The stability in promoter holding over the past months suggests a commitment to the company’s long-term vision. This lack of fluctuation in ownership could be interpreted as a sign of confidence from the promoters. Nevertheless, the company must work on improving profitability metrics to attract institutional investors and bolster overall investor confidence.
Outlook, Risks, and Final Insight
Vaishali Pharma faces several challenges and opportunities moving forward. The company has demonstrated a capacity to grow its sales, as evidenced by the recent quarterly performance, but profitability remains a critical concern, particularly with a net profit of zero in FY 2023. The volatility in revenue and declining profit margins present risks that could hinder future growth. However, with a strong liquidity position and manageable debt, Vaishali Pharma is well-positioned to navigate these challenges. The ongoing focus on operational efficiency and cost management will be essential in improving profitability. Should the company manage to stabilize its revenue and enhance margins, it could attract institutional investors and improve its market valuation. Conversely, continued stagnation in profits could deter investment and limit growth potential. The next few quarters will be pivotal as the company seeks to regain momentum and restore investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 105 Cr. | 27.2 | 796/25.8 | 1.02 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 1,637 Cr. | 162 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 46.0 Cr. | 3.61 | 8.65/3.48 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,557.17 Cr | 221.81 | 405.48 | 219.27 | 0.25% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.18 | 13.16 | 20.09 | 26.24 | 13.42 | 12.57 | 27.90 | 32.40 | 18.08 | 20.79 | 27.91 | 32.25 | 23.75 |
| Expenses | 7.98 | 10.57 | 16.53 | 25.46 | 11.11 | 9.92 | 24.95 | 39.19 | 15.73 | 18.37 | 26.55 | 38.29 | 22.38 |
| Operating Profit | 2.20 | 2.59 | 3.56 | 0.78 | 2.31 | 2.65 | 2.95 | -6.79 | 2.35 | 2.42 | 1.36 | -6.04 | 1.37 |
| OPM % | 21.61% | 19.68% | 17.72% | 2.97% | 17.21% | 21.08% | 10.57% | -20.96% | 13.00% | 11.64% | 4.87% | -18.73% | 5.77% |
| Other Income | 0.43 | 0.74 | 0.53 | 0.53 | 0.36 | 0.30 | 0.47 | 0.91 | 0.42 | 0.71 | 1.07 | 1.00 | 0.84 |
| Interest | 0.53 | 0.53 | 0.42 | 0.54 | 0.43 | 0.47 | 0.43 | 0.40 | 0.38 | 0.38 | 0.38 | 0.44 | 0.33 |
| Depreciation | 0.09 | 0.14 | 0.12 | 0.15 | 0.12 | 0.12 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 |
| Profit before tax | 2.01 | 2.66 | 3.55 | 0.62 | 2.12 | 2.36 | 2.87 | -6.42 | 2.27 | 2.63 | 1.93 | -5.60 | 1.74 |
| Tax % | 24.88% | 24.81% | 25.07% | 29.03% | 25.00% | 27.97% | 26.13% | -26.95% | 25.11% | 25.10% | 24.87% | -23.39% | 26.44% |
| Net Profit | 1.51 | 1.99 | 2.66 | 0.44 | 1.59 | 1.70 | 2.11 | -4.68 | 1.70 | 1.97 | 1.44 | -4.29 | 1.28 |
| EPS in Rs | 0.14 | 0.19 | 0.25 | 0.04 | 0.15 | 0.16 | 0.20 | -0.44 | 0.16 | 0.18 | 0.13 | -0.40 | 0.12 |
Last Updated: August 20, 2025, 1:35 am
Below is a detailed analysis of the quarterly data for Vaishali Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 23.75 Cr.. The value appears to be declining and may need further review. It has decreased from 32.25 Cr. (Mar 2025) to 23.75 Cr., marking a decrease of 8.50 Cr..
- For Expenses, as of Jun 2025, the value is 22.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.29 Cr. (Mar 2025) to 22.38 Cr., marking a decrease of 15.91 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from -6.04 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 7.41 Cr..
- For OPM %, as of Jun 2025, the value is 5.77%. The value appears strong and on an upward trend. It has increased from -18.73% (Mar 2025) to 5.77%, marking an increase of 24.50%.
- For Other Income, as of Jun 2025, the value is 0.84 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.84 Cr., marking a decrease of 0.16 Cr..
- For Interest, as of Jun 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.44 Cr. (Mar 2025) to 0.33 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Jun 2025, the value is 0.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.74 Cr.. The value appears strong and on an upward trend. It has increased from -5.60 Cr. (Mar 2025) to 1.74 Cr., marking an increase of 7.34 Cr..
- For Tax %, as of Jun 2025, the value is 26.44%. The value appears to be increasing, which may not be favorable. It has increased from -23.39% (Mar 2025) to 26.44%, marking an increase of 49.83%.
- For Net Profit, as of Jun 2025, the value is 1.28 Cr.. The value appears strong and on an upward trend. It has increased from -4.29 Cr. (Mar 2025) to 1.28 Cr., marking an increase of 5.57 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.40 (Mar 2025) to 0.12, marking an increase of 0.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 95 | 67 | 64 | 68 | 75 | 60 | 54 | 76 | 70 | 86 | 99 | 117 |
| Expenses | 118 | 95 | 66 | 60 | 65 | 73 | 59 | 51 | 69 | 60 | 85 | 98 | 119 |
| Operating Profit | 2 | -0 | 1 | 3 | 3 | 2 | 1 | 3 | 7 | 9 | 2 | 1 | -2 |
| OPM % | 2% | -0% | 1% | 5% | 4% | 3% | 2% | 5% | 9% | 13% | 2% | 1% | -2% |
| Other Income | 1 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Profit before tax | 1 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 6 | 9 | 1 | 1 | -0 |
| Tax % | 50% | -7% | 300% | 32% | 41% | 37% | 62% | 26% | 30% | 25% | 23% | 34% | |
| Net Profit | 0 | 0 | -0 | 1 | 1 | 1 | 0 | 1 | 4 | 7 | 1 | 1 | -0 |
| EPS in Rs | 0.38 | 0.20 | -0.04 | 0.15 | 0.08 | 0.07 | 0.00 | 0.10 | 0.38 | 0.63 | 0.07 | 0.08 | -0.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 300.00% | 75.00% | -85.71% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | -100.00% | 400.00% | -225.00% | -160.71% | 85.71% |
Vaishali Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 11% |
| 3 Years: | 9% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 94% |
| 3 Years: | -41% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 8% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 1:50 pm
Balance Sheet
Last Updated: December 10, 2025, 3:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 3 | 7 | 7 | 11 | 11 | 11 | 11 | 11 | 26 | 26 |
| Reserves | 3 | 3 | 3 | 1 | 14 | 15 | 11 | 12 | 16 | 30 | 32 | 39 | 41 |
| Borrowings | 19 | 25 | 21 | 23 | 18 | 17 | 17 | 18 | 21 | 15 | 13 | 12 | 16 |
| Other Liabilities | 32 | 17 | 25 | 18 | 25 | 30 | 28 | 46 | 34 | 24 | 24 | 33 | 39 |
| Total Liabilities | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
| Fixed Assets | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Other Assets | 53 | 44 | 48 | 43 | 62 | 67 | 64 | 84 | 80 | 76 | 77 | 107 | 114 |
| Total Assets | 53 | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 82 | 79 | 80 | 110 | 122 |
Below is a detailed analysis of the balance sheet data for Vaishali Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
- For Reserves, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 2.00 Cr..
- For Borrowings, as of Sep 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 33.00 Cr. (Mar 2025) to 39.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 107.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 7.00 Cr..
- For Total Assets, as of Sep 2025, the value is 122.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 122.00 Cr., marking an increase of 12.00 Cr..
Notably, the Reserves (41.00 Cr.) exceed the Borrowings (16.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -17.00 | -25.00 | -20.00 | -20.00 | -15.00 | -15.00 | -16.00 | -15.00 | -14.00 | -6.00 | -11.00 | -11.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 116 | 133 | 221 | 214 | 240 | 240 | 286 | 453 | 282 | 281 | 209 | 172 |
| Inventory Days | 26 | 13 | 20 | 7 | 11 | 5 | 6 | 5 | 4 | 20 | 2 | 20 |
| Days Payable | 99 | 66 | 145 | 100 | 136 | 130 | 169 | 321 | 163 | 120 | 95 | 116 |
| Cash Conversion Cycle | 43 | 80 | 96 | 121 | 115 | 115 | 123 | 137 | 122 | 181 | 116 | 77 |
| Working Capital Days | 59 | 98 | 25 | 14 | 97 | 98 | 124 | 146 | 111 | 208 | 169 | 231 |
| ROCE % | 19% | 14% | 13% | 16% | 13% | 10% | 7% | 10% | 19% | 22% | 6% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.06 | 0.68 | 6.26 | 3.82 | 0.99 |
| Diluted EPS (Rs.) | 0.06 | 0.64 | 5.91 | 3.82 | 0.99 |
| Cash EPS (Rs.) | 0.09 | 1.14 | 6.74 | 4.25 | 1.40 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 4.98 | 33.41 | 31.26 | 24.99 | 21.26 |
| Revenue From Operations / Share (Rs.) | 7.59 | 80.49 | 66.05 | 71.89 | 50.99 |
| PBDIT / Share (Rs.) | 0.25 | 2.96 | 10.77 | 8.20 | 4.21 |
| PBIT / Share (Rs.) | 0.21 | 2.48 | 10.29 | 7.76 | 3.81 |
| PBT / Share (Rs.) | 0.09 | 0.86 | 8.39 | 5.43 | 1.33 |
| Net Profit / Share (Rs.) | 0.06 | 0.67 | 6.26 | 3.81 | 0.99 |
| PBDIT Margin (%) | 3.32 | 3.67 | 16.30 | 11.39 | 8.26 |
| PBIT Margin (%) | 2.83 | 3.08 | 15.58 | 10.79 | 7.46 |
| PBT Margin (%) | 1.23 | 1.07 | 12.69 | 7.55 | 2.61 |
| Net Profit Margin (%) | 0.82 | 0.83 | 9.47 | 5.30 | 1.94 |
| Return on Networth / Equity (%) | 1.25 | 2.00 | 20.02 | 15.26 | 4.66 |
| Return on Capital Employeed (%) | 4.02 | 5.68 | 23.17 | 27.57 | 14.94 |
| Return On Assets (%) | 0.74 | 0.89 | 8.36 | 4.92 | 1.21 |
| Long Term Debt / Equity (X) | 0.06 | 0.10 | 0.15 | 0.11 | 0.18 |
| Total Debt / Equity (X) | 0.17 | 0.35 | 0.41 | 0.78 | 0.71 |
| Asset Turnover Ratio (%) | 1.04 | 1.09 | 0.86 | 0.90 | 0.70 |
| Current Ratio (X) | 2.61 | 2.25 | 2.27 | 1.47 | 1.37 |
| Quick Ratio (X) | 2.49 | 2.24 | 2.17 | 1.46 | 1.36 |
| Inventory Turnover Ratio (X) | 38.16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.08 | 1.83 | 5.66 | 3.52 | 1.70 |
| Interest Coverage Ratio (Post Tax) (X) | 1.52 | 1.41 | 4.29 | 2.64 | 1.40 |
| Enterprise Value (Cr.) | 173.94 | 161.15 | 166.55 | 89.17 | 49.85 |
| EV / Net Operating Revenue (X) | 1.76 | 1.87 | 2.39 | 1.18 | 0.92 |
| EV / EBITDA (X) | 52.78 | 50.82 | 14.66 | 10.32 | 11.22 |
| MarketCap / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| Price / BV (X) | 2.53 | 4.19 | 4.67 | 2.65 | 1.53 |
| Price / Net Operating Revenue (X) | 1.66 | 1.74 | 2.21 | 0.92 | 0.63 |
| EarningsYield | 0.00 | 0.00 | 0.04 | 0.05 | 0.03 |
After reviewing the key financial ratios for Vaishali Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.68 (Mar 24) to 0.06, marking a decrease of 0.62.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.64 (Mar 24) to 0.06, marking a decrease of 0.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has decreased from 1.14 (Mar 24) to 0.09, marking a decrease of 1.05.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.59. It has decreased from 80.49 (Mar 24) to 7.59, marking a decrease of 72.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 2.96 (Mar 24) to 0.25, marking a decrease of 2.71.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 2.48 (Mar 24) to 0.21, marking a decrease of 2.27.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.09, marking a decrease of 0.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has decreased from 0.67 (Mar 24) to 0.06, marking a decrease of 0.61.
- For PBDIT Margin (%), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 10. It has decreased from 3.67 (Mar 24) to 3.32, marking a decrease of 0.35.
- For PBIT Margin (%), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 2.83, marking a decrease of 0.25.
- For PBT Margin (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 10. It has increased from 1.07 (Mar 24) to 1.23, marking an increase of 0.16.
- For Net Profit Margin (%), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 5. It has decreased from 0.83 (Mar 24) to 0.82, marking a decrease of 0.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 15. It has decreased from 2.00 (Mar 24) to 1.25, marking a decrease of 0.75.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 10. It has decreased from 5.68 (Mar 24) to 4.02, marking a decrease of 1.66.
- For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 0.89 (Mar 24) to 0.74, marking a decrease of 0.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.17, marking a decrease of 0.18.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 2.61, marking an increase of 0.36.
- For Quick Ratio (X), as of Mar 25, the value is 2.49. This value exceeds the healthy maximum of 2. It has increased from 2.24 (Mar 24) to 2.49, marking an increase of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 38.16. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 38.16, marking an increase of 38.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.08. This value is below the healthy minimum of 3. It has increased from 1.83 (Mar 24) to 2.08, marking an increase of 0.25.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 24) to 1.52, marking an increase of 0.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 173.94. It has increased from 161.15 (Mar 24) to 173.94, marking an increase of 12.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 1.87 (Mar 24) to 1.76, marking a decrease of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 52.78. This value exceeds the healthy maximum of 15. It has increased from 50.82 (Mar 24) to 52.78, marking an increase of 1.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For Price / BV (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 4.19 (Mar 24) to 2.53, marking a decrease of 1.66.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vaishali Pharma Ltd:
- Net Profit Margin: 0.82%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.02% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.25% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 405.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.82%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 706 to 709, 7th Floor, Aravali Business Center, Mumbai Maharashtra 400092 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Atul Arvind Vasani | Chairman & Managing Director |
| Mr. Dewansh Ajay Vasani | Executive Director & CFO |
| Mrs. Jagruti Atul Vasani | Whole Time Director |
| Mr. Manish Bhagwandas Ved | Ind. Non-Executive Director |
| Mr. Pratik Vikram Jakhelia | Ind. Non-Executive Director |
| Mr. Bhaveshkumar Upadhyay | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Vaishali Pharma Ltd?
Vaishali Pharma Ltd's intrinsic value (as of 25 December 2025) is 0.96 which is 89.67% lower the current market price of 9.29, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 121 Cr. market cap, FY2025-2026 high/low of 18.8/7.75, reserves of ₹41 Cr, and liabilities of 122 Cr.
What is the Market Cap of Vaishali Pharma Ltd?
The Market Cap of Vaishali Pharma Ltd is 121 Cr..
What is the current Stock Price of Vaishali Pharma Ltd as on 25 December 2025?
The current stock price of Vaishali Pharma Ltd as on 25 December 2025 is 9.29.
What is the High / Low of Vaishali Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vaishali Pharma Ltd stocks is 18.8/7.75.
What is the Stock P/E of Vaishali Pharma Ltd?
The Stock P/E of Vaishali Pharma Ltd is .
What is the Book Value of Vaishali Pharma Ltd?
The Book Value of Vaishali Pharma Ltd is 5.16.
What is the Dividend Yield of Vaishali Pharma Ltd?
The Dividend Yield of Vaishali Pharma Ltd is 0.00 %.
What is the ROCE of Vaishali Pharma Ltd?
The ROCE of Vaishali Pharma Ltd is 4.93 %.
What is the ROE of Vaishali Pharma Ltd?
The ROE of Vaishali Pharma Ltd is 1.52 %.
What is the Face Value of Vaishali Pharma Ltd?
The Face Value of Vaishali Pharma Ltd is 2.00.